Stem cell heart failure treatment advances

Posted: July 12, 2014 at 5:44 pm

Stem cells grown under low oxygen. These stem cells from Stemedica are licensed to CardioCell.

CardioCell, a San Diego stem cell company, has started a Phase 2a trial of its treatment for chronic heart failure.

The companys special stem cells will be injected into patients with heart failure not caused by a heart attack. Nearly 2 million Americans have that kind of heart failure.

CardioCell is also testing these stem cells on heart attack patients to help their recovery. The cells are licensed from Stemedica, CardioCell's parent company.

Taken from bone marrow, the stem cells produce chemicals intended to heal malfunctioning heart cells. They are grown under low oxygen conditions, or hypoxia. CardioCell says hypoxia reflects the conditions under which natural stem cells exist. Histogen, also of San Diego, is developing its own kind of low-oxygen stem cells.

Growing stem cells with abundant oxygen reduces their "stemness," and they become prone to differentiate, said Sergey Sikora, CardioCell's president and chief executive.

Sergey Sikora, president and CEO of CardioCell / CardioCell

More than 20 patients are being sought to take part in the study, which is taking place at three locations. These are Emory University in Atlanta, Northwestern University in Chicago, and the University of Pennsylvania in Philadelphia.

Patients will receive injections of the stem cells, and a control group will receive a saline injection. After 90 days, the groups will be reversed. Patients who had received the stem cells will get a saline injection, and the control group will get the stem cells.

The stem cells last for about a month, after which they disappear, Sikora said.

Read this article:
Stem cell heart failure treatment advances

Related Post

Comments are closed.